Bromhexine Hydrochloride

Specifications

611-75-6CAS Number

210-280-8EC Number

2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline;hydrochlorideIUPAC Name

C14H21Br2ClN2Chemical Formula

412.59 g/molMolecular Weight

Bromhexine hydrochloride; 611-75-6; Bromhexine HCl; Bisolvon; Auxit; Broncokin; Viscolyt; Bromhexine chloride; Quentan; Bromohexine monohydrochloride; NA 274; Bromehexine hydrochloride; DTXSID0045886; YC2ZOM3Z8V; NSC-758383; NA-274; N-Cyclohexyl-N-methyl-(2-amino-3,5-dibromobenzyl)ammonium chloride; DTXCID8025886; CHEBI:31303; 2-Amino-N-cyclohexyl-3,5-dibromo-N-methylbenzylamine hydrochloride; N-(2-Amino-3,5-dibromobenzyl)-N-methyl-cyclohexylammonium chloride; Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-, monohydrochloride; RefChem:6621; Hydrochloride, Bromhexine; Bromhexine Monohydrochloride; Monohydrochloride, Bromhexine; 2-Amino-3,5-dibromo-N-cyclohexyl-N-methylbenzylamine monohydrochloride; 210-280-8; 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride; Bromhexine (hydrochloride); MFCD00056626; NCGC00095005-01; 2,4-Dibromo-6-[(cyclohexyl-methyl-amino)-methyl]-phenylamine; N-(2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine hydrochloride; 2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline hydrochloride; Bromessina; Lisomucin; 2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline;hydrochloride; C14H21Br2ClN2; CAS-611-75-6; Bromessina [Italian]; Bromihexine hydrochloride; UNII-YC2ZOM3Z8V; Ophtolsol; [(2-amino-3,5-dibromophenyl)methyl]cyclohexylmethylamine, chloride; SR-05000001825; Bisolvon (TN); EINECS 210-280-8; Bromhexine hydrochloride [USAN:JAN]; BROMBENZONIUM; 611-75-6 (HCl); 2-Amino-3,5-dibromo-N-cyclohexyl-N-methylbenzylamine hydrochloride; Bromhexine hydrochloride CRS; SCHEMBL99613; SPECTRUM1503107; HY-B0372AR; orb1310255; CHEMBL1319139; SCHEMBL10704011; HY-B0372A; GLXC-06089; HMS1922E19; HMS5080A04; Pharmakon1600-01503107; MSK10772; Tox21_111385; BROMHEXINE HYDROCHLORIDE [MI]; CCG-39304; EBC-07637; NSC758383; s2060; SBB001448; Bromhexine for system suitability CRS; BROMHEXINE HYDROCHLORIDE [JAN]; AKOS015906433; Benzylamine, 2-amino-N-cyclohexyl-3,5-dibromo-N-methyl-, hydrochloride; Bromhexine (hydrochloride) (Standard); Tox21_111385_1; AC-6857; Bromhexine hydrochloride (JP18/USAN); BROMHEXINE HYDROCHLORIDE [USAN]; FB64964; KS-5253; NSC 758383; BROMHEXINE HYDROCHLORIDE [MART.]; BROMHEXINE HYDROCHLORIDE [WHO-DD]; NCGC00095005-02; NCGC00178520-03; 3,5-Dibromo-N(sup alpha)-cyclohexyl-N(sup alpha)-methyltoluene-alpha,2-diamine monohydrochloride; ST007548; SY046825; Bromhexine hydrochloride, >=98.0% (AT); B4054; B6957; Bromhexine hydrochloride, analytical standard; NS00021246; SW199599-2; BROMHEXINE HYDROCHLORIDE [EP MONOGRAPH]; D01778; D70838; EN300-651495; F807027; SR-05000001825-2; Q27114269; Bromhexine Hydrochloride 1.0 mg/ml in Methanol (as free base); 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)anilinehydrochloride; N-(2-Amino-3,5-dibromobenzyl)-N-methylcyclohexanamine hydrochloride; N-(2-amino-3,5-dibromobenzyl)-N-methylcyclohexanaminium chloride; Bromhexine hydrochloride, European Pharmacopoeia (EP) Reference Standard; 2,4-Dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline--hydrogen chloride (1/1); 3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha,2-diamine monohydrochloride; Bromhexine for system suitability, European Pharmacopoeia (EP) Reference Standard; Bromhexine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material; 3,5-DIBROMO-N(SUP .ALPHA.)-CYCLOHEXYL-N(SUP .ALPHA.)-METHYLTOLUENE-.ALPHA.,2-DIAMINE MONOHYDROCHLORIDE; Toluene-alpha,2-diamine, 3,5-dibromo-N(sup alpha)-cyclohexyl-N-(sup alpha)-methyl-, monohydrochlorideSynonyms